
About CytoReason
CytoReason is a Healthcare company based in Haifa (Israel) founded in 2016. Immune system-based drugs are discovered via biological data analytics. CytoReason has raised $100 million across 3 funding rounds from investors including Thermo Fisher Scientific, Nvidia and OurCrowd. CytoReason offers products and services including Disease Model and Drug Portfolio Manager. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is CytoReason LTD.
Company details
CytoReason was founded in 2016 in Haifa, Israel, within the biotechnology sector. Immune system-based drugs are developed through a proprietary platform that integrates scientific and experimental data. The immune system is stimulated and analyzed using high-resolution patient data alongside scientific research to support drug discovery processes. Operations focus on biological data analytics for therapeutic advancements.
- Headquarters Haifa, Israel
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website cytoreason.com
- Social LinkedIn X
- Legal Name Cytoreason Ltd
- Total Equity Funding$100M (USD)
in 3 rounds
- Latest Funding Round$80M (USD), Series C
Jul 2024
- InvestorsThermo Fisher Scientific
& 4 more
Products & Services of CytoReason
CytoReason offers a comprehensive portfolio of products and services, including Disease Model and Drug Portfolio Manager.
AI tool for modeling diseases and comparing treatments.
Platform to prioritize and compare drug programs across populations.
Funding Insights of CytoReason
CytoReason has successfully raised a total of $100M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $80 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $100M
- Total Rounds 3
- Last Round Series C β $80M
- First Round $20M
(Sep 2022)
- Investors Count 5
All 3 funding rounds of CytoReason with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
5 investors in total: 5 institutional.
Investors in CytoReason
CytoReason has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include Thermo Fisher Scientific, Nvidia and OurCrowd.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States | |
Secondary fund investments are emphasized by this Israeli commercial bank. | 1921 | bankhapoalim.com | Tel Aviv, Israel | |
Network connecting investors to startups, venture capital funds, and alternatives | 2013 | ourcrowd.com | Jerusalem, Israel | |
AI-powered graphical processing units and SoCs | 1993 | nvidia.com | Santa Clara, United States | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | thermofisher.com | Waltham, United States |
Investor details for CytoReason
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CytoReason
43 people are tracked at CytoReason (12 in leadership, 10 in board & advisors, 21 in team).
| Name | Role | Group |
|---|---|---|
Shai Shen-Orr | Co-Founder & Chief Scientist | Leadership |
David Harel | Chief Executive Officer | Leadership |
eldad kadari | Vp, Business Development - Biopharma Solutions | Leadership |
Nicole Van Poppel | Chief Business Officer | Leadership |
Yehuda Chowers | Chief Medical Officer | Leadership |
Noam Hadary | Director Of Model Team | Leadership |
Liza Aizman | Senior Director Of Science Operations, Immune-oncology | Leadership |
Yoav Aharoni | VP, R&D | Leadership |
Elina Starosvetsky | Co-Founder & VP, Biology | Leadership |
Alexandra Sirota-Madi | VP Of Science Operations | Leadership |
Tim O'Brien | Vice President Business Development And Sales | Leadership |
Ronen Schuster | Director Science Operations | Leadership |
Jeremy Goldberg | Director | Board & advisors |
Chris Sander | Advisor | Board & advisors |
John Tsang | Advisor | Board & advisors |
Michael Vincent | Advisor | Board & advisors |
Tom Bumol | Advisor | Board & advisors |
JC Gutiérrez-Ramos | Advisor | Board & advisors |
Fabian Theis | Advisor | Board & advisors |
Martin Wales | Director | Board & advisors |
23 more people are available in the full profile.
Complete people profiles for CytoReason
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CytoReason
3 dated milestones of CytoReason across 8 years, from founding to its latest funding, stage changes and deals.
- Founded CytoReason is founded.
- Funding First funding round of $20.0M.
- Funding Latest funding round, Series C, of $80.0M.
Web traffic of CytoReason
The website of CytoReason (cytoreason.com) receives about 2.9K visits a month and ranks #2,644,026 among all websites worldwide, #3,609 in Biotechnology and Pharmaceuticals.
- Monthly visits2.9K
▼ 8.1% vs previous month
- Unique visitors1.3K
per month
- Global rank#2,644,026
among all websites
- Category rank#3,609
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit11.6
- Average visit5 min 26 sec
- DevicesDesktop 11% Β· Mobile 89%
Websites whose visitors overlap most with CytoReason. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| crohnscolitisfoundation.org | 100% | 258.8K | #196,222 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cytoreason
Complete news archive for CytoReason
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CytoReason
CytoReason was founded in 2016 and raised its 1st funding round 6 years after it was founded.
CytoReason is headquartered in Haifa, Israel. It is registered at Haifa, Haifa District, Israel.
CytoReason is a funded company, having raised a total of $100M across 3 funding rounds to date. The company's 1st funding round was a Series B of $20M, raised on Sep 2022.
CytoReason was founded in 2016 in Haifa, Israel, within the biotechnology sector. Immune system-based drugs are developed through a proprietary platform that integrates scientific and experimental data. The immune system is stimulated and analyzed using high-resolution patient data alongside scientific research to support drug discovery processes. Operations focus on biological data analytics for therapeutic advancements.
CytoReason offers Disease Model and Drug Portfolio Manager.
CytoReason has 5 investors. Key investors include Thermo Fisher Scientific, Nvidia, OurCrowd, Pfizer, and Bank Hapoalim.
CytoReason operates through Cytoreason Ltd.
